|
1
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boolell V, Alamgeer M, Watkins DN and
Ganju V: The evolution of therapies in non-small cell lung cancer.
Cancers. 7:1815–1846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rikova K, Guo A, Zeng Q, Possemato A, Yu
J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey
of phosphotyrosine signaling identifies oncogenic kinases in lung
cacner. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zou HY, Li Q, Lee JH, Arango ME, McDonnell
SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, et al: An
orally available small-molecule inhibitor of c-Met, PF-2341066,
exhibits cytoreductive antitumor efficacy through antiproliferative
and antiangiogenic mechanisms. Cancer Res. 67:4408–4417. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ,
Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, et
al: Activity and safety of crizotinib in patients with ALK-positive
non-small-cell lung cancer: Updated results from a phase 1 study.
Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crino L, Kim D, Riely GJ, Janne PA,
Blackhall FH, Camidge DR, Hirsh V, Mok T, Solomon BJ, Park K, et
al: Initial phase II results with crizotinib in advanced
ALK-posivie non-small cell lung cancer (NSCLC): PROFILE 1005. ASCO
Meet Abstr. 29 15 Suppl:75142011.
|
|
9
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cacner. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu S, Mok T, Lu Y, Zhou J, Shi Y and
Sriuranpong V: Phase 3 study of first-line crizotinib vs
pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts)
with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).
ASCO Meet Abstr. 34 15 Suppl:90582016.
|
|
12
|
Rami-Porta R, Bolejack V, Giroux DJ,
Chansky K, Crowley J, Asamura H and Goldstraw P: International
Association for the Study of Lung Cancer Staging and Prognostic
Factors Committee, Advisory Board Members and Participating
Institutions: The IASLC lung cancer staging project: The new
database to inform the eighth edition of the TNM classfication of
lung cancer. J Thorac Oncol. 9:1618–1624. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wynes MW, Sholl LM, Dietel M, Schuuring E,
Tsao MS, Yatabe Y, Tubbs RR and Hirsch FR: An international
interpretation study using the ALK IHC antibody D5F3 and a
sensitive detection kit demonstrates high concordance between ALK
IHC and ALK FISH and between evaluators. J Thorac Oncol. 9:631–638.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Melosky B: Current treatment algorithms
for patients with metastatic non-small cell, non-squamous lung
cancer. Front Oncol. 7:382017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodig SJ, Mino-Kenudson M, Dacic S, Yeap
BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, et
al: Unique clinicopathologic features characterize ALK-rearranged
lung adenocarcinoma in the western population. Clin Cancer Res.
15:5216–5223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang YG, Jin ML, Li L, Zhao HY, Zeng X,
Jiang L, Wei P, Diao XL, Li X, Cao Q and Tian XX: Evaluation of ALK
rearrangement in Chinese non-small cell lung cancer using FISH,
immunohistochemistry, and real-time quantitative RT-PCR on
paraffin-embedded tissues. PLoS One. 8:e648212013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Doebele RC, Lu X, Sumey C, Maxson DA,
Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner
DL, et al: Oncogene status predicts patterns of metastatic spread
in treatment-naïve non-small cell lung cancer. Cancer.
118:4502–4511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seto T, Kiura K, Nishio M, Nakagawa K,
Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, et
al: CH5424802(RO5424802) for patients with ALK-rearranged advanced
non-small-cell lung cancer (AF-001JP study): A single-arm,
open-label, phase 1–2 study. Lancet Oncol. 14:590–598. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thun MJ, Carter BD, Feskanich D, Freedman
ND, Prentice R, Lopez AD, Hartge P and Gapstur SM: 50-year trends
in smoking-related mortality in the United States. N Engl J Med.
368:351–364. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jha P, Ramasundarahettige C, Landsman V,
Rostron B, Thun M, Anderson RN, McAfee T and Peto R: 21st-century
hazards of smoking and benefits of cessation in the United States.
N Engl J Med. 368:341–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen G, Chen X, Zhang Y, Yan F, Fang W,
Yang Y, Hong S, Miao S, Wu M, Huang X, et al: A large,
single-center, real-world study of clinicopathological
characteristics and treatment in advanced ALK-positive
non-small-cell lung cancer. Cancer Med. 6:953–961. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshida T, Oya Y, Tanaka K, Shimizu J,
Horio Y, Kuroda H, Sakao Y, Hida T and Yatabe Y: Differential
crizotinib response duration among ALK fusion variants in
ALK-positive non-small-cell lung cancer. J Clin Oncol.
34:3383–3389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cha YJ, Kim HR and Shim HS: Clinical
outcomes in ALK-rearranged lung adenocarcinomas according to ALK
fusion variants. J Transl Med. 14:2962016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shaw AT, Yeap BY, Solomon BJ, Riely GJ,
Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et
al: Effect of crizotinib on overall survival in pateints with
advanced non-small-cell lung cancer harbouring ALK gene
rearrangement: A retrospective analysis. Lancet Oncol.
12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Costa DB, Shaw AT, Ou SH, Solomon BJ,
Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, et al:
Clinical experience with crizotinib in patients with advanced
ALK-rearranged non-small-cell lung cancer and brain metastasis. J
Clin Oncol. 33:1881–1888. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Camidge DR: Taking aim at ALK across the
blood-brain barrier. J Thorac Oncol. 8:389–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Metro G, Lunardi G, Floridi P, Pascali JP,
Marcomigni L, Chiari R, Ludovini V, Crinò L and Gori S: CSF
concentration of crizotinib in two ALK-positive non-small-cell lung
cancer patients with CNS metastases deriving clinical benefit from
treatment. J Thorac Oncol. 10:e26–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ou SH, Ahn JS, De Petris L, Govindan R,
Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, et
al: Alectinib in crizotinib-refractory ALK-rearranged
non-small-cell lung cancer: A phase II global study. J Clin Oncol.
34:661–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shaw AT, Gandhi L, Gadgeel S, Riely GJ,
Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T,
et al: Alectinib in ALK-positive, crizotinib-resistant,
non-small-cell lung cancer: A single-group, multicentre, phase 2
trial. Lancet Oncol. 17:234–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Costa DB, Kobayashi S, Pandya SS, Yeo WL,
Shen Z, Tan W and Wilner KD: CSF concentration of the anaplastic
lymphoma kinase inhibitor crizotinib. J Clin Oncol. 29:e443–445.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Metro G, Lunardi G, Floridi P, Pascali JP,
Marcomigni L, Chiari R, Ludovini V, Crinò L and Gori S: CSF
concentration of crizotinib in two ALK-positive non-small-cell lung
cancer patients with CNS metastases deriving clinical benefit from
treatment. J Thorac Oncol. 10:e26–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim
DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW and Riely
GJ: Clinical benefit of continuing ALK inhibition with crizotinib
beyond initial disease progression in patients with advanced
ALK-positive NSCLC. Ann Oncol. 25:415–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hong X, Chen Q, Ding L, Liang Y, Zhou N,
Fang W, Chen X and Wu H: Clinical benefit of continuing crizotinib
therapy after initial disease progression in Chiniese pateints with
advanced ALK-rearranged non-small-cell lung cancer. Oncotarget.
8:41631–41640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Takeda M, Okamoto I and Nakagawa K:
Clinical impact of continued crizotinib administration after
isolated central nervous system progresssion in patients with lung
cancer positive for ALK rearrangement. J Thorac Oncol. 8:654–657.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weickhardt AJ, Scheier B, Burke JM, Gan G,
Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC and
Camidge DR: Local ablative therapy of oligoprogressive disease
prolongs disease control by tyrosine kinase inhibitors in
oncogene-addicted non-small-cell lung cacner. J Thorac Oncol.
7:1807–1814. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bendaly E, Dalal AA, Culver K, Galebach P,
Bocharova I, Foster R, Sasane M, Macalalad AR and Guérin A:
Monitoring for and characterizing crizotinib progression: A chart
review of ALK-positive non-small cell lung cancer pateints. Adv
Ther. 34:1673–1685. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu JJ, Savooji J and Liu DL: Second- and
third-generation ALK inhibitors for non-small cell lung cancer. J
Hematol Oncol. 9:192016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Su S and Wu YL: Clinical trials of
tyrosine kinase inhibitors for lung cancer in China: A review. J
Hematol Oncol. 10:1472017. View Article : Google Scholar : PubMed/NCBI
|
